Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117457) titled 'Clinical Characteristics of Osimertinib-Related Cardiac Toxicity' on Jan. 23.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The First Affiliated Hospital of Wenzhou Medical University
Condition:
Cardiac toxicity adverse events include heart failure, pericardial effusion, and decreased left ventricular function. Laboratory abnormalities include elevated CK-MB, cTNT, NT-proBNP, and electrocardiogram abnormalities (QT interval changes).
Intervention:
No-Cardiotoxicity Group:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-30
Target Sample...